NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 74.6% and is now trading at $440.70.
View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for DexCom.

DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Tuesday, July, 28th. The medical device company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.48. The medical device company earned $451.80 million during the quarter, compared to analysts' expectations of $415.21 million. DexCom had a net margin of 11.93% and a return on equity of 29.01%. DexCom's revenue was up 34.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 earnings per share.
View DexCom's earnings history.

DexCom updated its FY 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.85 billion, compared to the consensus revenue estimate of $1.8 billion.

21 analysts have issued twelve-month price objectives for DexCom's stock. Their forecasts range from $190.00 to $500.00. On average, they anticipate DexCom's stock price to reach $393.20 in the next twelve months. This suggests that the stock has a possible downside of 10.8%.
View analysts' price targets for DexCom.

News stories about DXCM stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about DexCom.

DexCom saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 4,400,000 shares, a drop of 7.8% from the June 15th total of 4,770,000 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is currently 2.4 days. Currently, 4.9% of the company's shares are sold short.
View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR), Insulet (PODD) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mint Tower Capital Management B.V. (8.20%), Jennison Associates LLC (2.88%), Sumitomo Mitsui Trust Holdings Inc. (0.48%), Swiss National Bank (0.38%), Frontier Capital Management Co. LLC (0.32%) and New York State Common Retirement Fund (0.25%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Columbus Circle Investors, Ardevora Asset Management LLP, Frontier Capital Management Co. LLC, Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, New York State Common Retirement Fund, and Victory Capital Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom.

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Principal Financial Group Inc., New York State Teachers Retirement System, Bessemer Group Inc., Jennison Associates LLC, ProShare Advisors LLC, Zweig DiMenna Associates LLC, and Retirement Systems of Alabama.
View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $440.70.

DexCom has a market capitalization of $42.19 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]